BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B; DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366-76. [PMID: 22077236 DOI: 10.1056/NEJMoa1111732] [Cited by in Crossref: 350] [Cited by in F6Publishing: 177] [Article Influence: 31.8] [Reference Citation Analysis]
Number Citing Articles
1 de Boer IH, Bakris GL. Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. Diabetes Care 2018;41:662-3. [PMID: 29559452 DOI: 10.2337/dci17-0053] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
2 Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016;32:21-39. [PMID: 25865292 DOI: 10.1002/dmrr.2653] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 11.6] [Reference Citation Analysis]
3 August P, Hardison RM, Hage FG, Marroquin OC, McGill JB, Rosenberg Y, Steffes M, Wall BM, Molitch M. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study. Clin J Am Soc Nephrol. 2014;9:64-71. [PMID: 24178969 DOI: 10.2215/cjn.12281211] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
4 Dounousi E, Duni A, Leivaditis K, Vaios V, Eleftheriadis T, Liakopoulos V. Improvements in the Management of Diabetic Nephropathy. Rev Diabet Stud 2015;12:119-33. [PMID: 26676665 DOI: 10.1900/RDS.2015.12.119] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
5 Shah I, Barker J, Naughton DP, Barton SJ, Ashraf SS. HPLC estimation of iothalamate to measure glomerular filtration rate in humans. Chem Cent J 2016;10:80. [PMID: 28028385 DOI: 10.1186/s13065-016-0227-3] [Reference Citation Analysis]
6 Vu TC, Nutt JG, Holford NH. Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. Br J Clin Pharmacol 2012;74:284-95. [PMID: 22300470 DOI: 10.1111/j.1365-2125.2012.04208.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
7 Allison SJ. Diabetes: Intensive glucose control in type 1 diabetes mellitus reduces risk of GFR loss. Nat Rev Nephrol 2011;8:1. [PMID: 22143332 DOI: 10.1038/nrneph.2011.176] [Reference Citation Analysis]
8 Li H, Zha X, Zhu Y, Liu M, Guo R, Wen Y. An Invert U-Shaped Curve: Relationship Between Fasting Plasma Glucose and Serum Uric Acid Concentration in a Large Health Check-Up Population in China. Medicine (Baltimore) 2016;95:e3456. [PMID: 27100447 DOI: 10.1097/MD.0000000000003456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 de Boer IH, Gao X, Cleary PA, Bebu I, Lachin JM, Molitch ME, Orchard T, Paterson AD, Perkins BA, Steffes MW, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clin J Am Soc Nephrol 2016;11:1969-77. [PMID: 27797889 DOI: 10.2215/CJN.02870316] [Cited by in Crossref: 61] [Cited by in F6Publishing: 22] [Article Influence: 10.2] [Reference Citation Analysis]
10 Nathan DM;  DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9-16. [PMID: 24356592 DOI: 10.2337/dc13-2112] [Cited by in Crossref: 765] [Cited by in F6Publishing: 596] [Article Influence: 109.3] [Reference Citation Analysis]
11 Kitada M, Kanasaki K, Koya D. Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes 2014; 5(3): 342-356 [PMID: 24936255 DOI: 10.4239/wjd.v5.i3.342] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
12 Ku E, McCulloch CE, Mauer M, Gitelman SE, Grimes BA, Hsu CY. Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes. Diabetes Care 2016;39:2218-24. [PMID: 27872156 DOI: 10.2337/dc16-0857] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
13 Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012;172:761-769. [PMID: 22636820 DOI: 10.1001/archinternmed.2011.2230] [Cited by in Crossref: 163] [Cited by in F6Publishing: 140] [Article Influence: 16.3] [Reference Citation Analysis]
14 Ding Q, Gao Z, Chen K, Zhang Q, Hu S, Zhao L. Inflammation-Related Epigenetic Modification: The Bridge Between Immune and Metabolism in Type 2 Diabetes. Front Immunol 2022;13:883410. [DOI: 10.3389/fimmu.2022.883410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Dart AB, Wicklow B, Blydt-Hansen TD, Sellers EAC, Malik S, Chateau D, Sharma A, McGavock JM. A Holistic Approach to Risk for Early Kidney Injury in Indigenous Youth With Type 2 Diabetes: A Proof of Concept Paper From the iCARE Cohort. Can J Kidney Health Dis 2019;6:2054358119838836. [PMID: 31041107 DOI: 10.1177/2054358119838836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Sandholm N, Van Zuydam N, Ahlqvist E, Juliusdottir T, Deshmukh HA, Rayner NW, Di Camillo B, Forsblom C, Fadista J, Ziemek D, Salem RM, Hiraki LT, Pezzolesi M, Trégouët D, Dahlström E, Valo E, Oskolkov N, Ladenvall C, Marcovecchio ML, Cooper J, Sambo F, Malovini A, Manfrini M, McKnight AJ, Lajer M, Harjutsalo V, Gordin D, Parkkonen M, Tuomilehto J, Lyssenko V, McKeigue PM, Rich SS, Brosnan MJ, Fauman E, Bellazzi R, Rossing P, Hadjadj S, Krolewski A, Paterson AD, Florez JC, Hirschhorn JN, Maxwell AP, Dunger D, Cobelli C, Colhoun HM, Groop L, McCarthy MI, Groop PH; The FinnDiane Study Group., The DCCT/EDIC Study Group., GENIE Consortium., SUMMIT Consortium. The Genetic Landscape of Renal Complications in Type 1 Diabetes. J Am Soc Nephrol 2017;28:557-74. [PMID: 27647854 DOI: 10.1681/ASN.2016020231] [Cited by in Crossref: 64] [Cited by in F6Publishing: 42] [Article Influence: 10.7] [Reference Citation Analysis]
17 de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Zinman B, Steffes MW; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Longitudinal changes in estimated and measured GFR in type 1 diabetes. J Am Soc Nephrol 2014;25:810-8. [PMID: 24309189 DOI: 10.1681/ASN.2013050557] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
18 Thomas MC, Brownlee M, Susztak K, Sharma K, Jandeleit-Dahm KA, Zoungas S, Rossing P, Groop PH, Cooper ME. Diabetic kidney disease. Nat Rev Dis Primers 2015;1:15018. [PMID: 27188921 DOI: 10.1038/nrdp.2015.18] [Cited by in Crossref: 148] [Cited by in F6Publishing: 162] [Article Influence: 21.1] [Reference Citation Analysis]
19 Bjornstad P, Pyle L, Kinney GL, Rewers M, Johnson RJ, Maahs DM, Snell-Bergeon JK. Adiponectin is associated with early diabetic kidney disease in adults with type 1 diabetes: A Coronary Artery Calcification in Type 1 Diabetes (CACTI) Study. J Diabetes Complications 2017;31:369-74. [PMID: 27368123 DOI: 10.1016/j.jdiacomp.2016.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
20 Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev 2018;9:CD011798. [PMID: 30246878 DOI: 10.1002/14651858.CD011798.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
21 Heukamp I, Then C, Lechner A, Seissler J. [Update on type 1 diabetes]. Internist (Berl) 2013;54:201-14; quiz 215-6. [PMID: 23247771 DOI: 10.1007/s00108-012-3174-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
22 Orchard TJ, Sun W, Cleary PA, Genuth SM, Lachin JM, McGee P, Paterson AD, Raskin P, Anbinder Y, Levy AP; DCCT/EDIC Research Group. Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes. 2013;62:3218-3223. [PMID: 23761102 DOI: 10.2337/db13-0256] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
23 Mottl AK, Alicic R, Argyropoulos C, Brosius FC, Mauer M, Molitch M, Nelson RG, Perreault L, Nicholas SB. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. American Journal of Kidney Diseases 2022. [DOI: 10.1053/j.ajkd.2021.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Nakamichi R, Hayashi K, Itoh H. Effects of High Glucose and Lipotoxicity on Diabetic Podocytes. Nutrients 2021;13:241. [PMID: 33467659 DOI: 10.3390/nu13010241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY, Wanner C, Kasiske BL, Wheeler DC, de Zeeuw D, Mogensen CE. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int 2015;87:20-30. [PMID: 24786708 DOI: 10.1038/ki.2014.128] [Cited by in Crossref: 134] [Cited by in F6Publishing: 110] [Article Influence: 16.8] [Reference Citation Analysis]
26 Orlov S, Cherney DZ, Pop-Busui R, Lovblom LE, Ficociello LH, Smiles AM, Warram JH, Krolewski AS, Perkins BA. Cardiac autonomic neuropathy and early progressive renal decline in patients with nonmacroalbuminuric type 1 diabetes. Clin J Am Soc Nephrol. 2015;10:1136-1144. [PMID: 26092828 DOI: 10.2215/cjn.11441114] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
27 Lambers Heerspink HJ, Gansevoort RT. Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View. Clin J Am Soc Nephrol 2015;10:1079-88. [PMID: 25887073 DOI: 10.2215/CJN.11511114] [Cited by in Crossref: 82] [Cited by in F6Publishing: 39] [Article Influence: 11.7] [Reference Citation Analysis]
28 Hanefeld M, Duetting E, Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol. 2013;12:135. [PMID: 24053606 DOI: 10.1186/1475-2840-12-135] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
29 MacIsaac RJ, Jerums G, Ekinci EI. Effects of glycaemic management on diabetic kidney disease. World J Diabetes 2017; 8(5): 172-186 [PMID: 28572879 DOI: 10.4239/wjd.v8.i5.172] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
30 Bjornstad P, Snell-Bergeon JK, Nadeau KJ, Maahs DM. Insulin sensitivity and complications in type 1 diabetes: New insights. World J Diabetes 2015; 6(1): 8-16 [PMID: 25685274 DOI: 10.4239/wjd.v6.i1.8] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
31 Menon MC, He JC. Prostaglandin I2 Receptor Agonism for Proteinuria and Diabetes: Good for the Goose and Good for the Gander? Diabetes 2016;65:1149-51. [PMID: 27208182 DOI: 10.2337/dbi16-0009] [Reference Citation Analysis]
32 Lambers Heerspink HJ, de Zeeuw D. Novel drugs and intervention strategies for the treatment of chronic kidney disease. Br J Clin Pharmacol 2013;76:536-50. [PMID: 23802504 DOI: 10.1111/bcp.12195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
33 Zhu S, Hou S, Lu Y, Sheng W, Cui Z, Dong T, Feng H, Wan Q. USP36-Mediated Deubiquitination of DOCK4 Contributes to the Diabetic Renal Tubular Epithelial Cell Injury via Wnt/β-Catenin Signaling Pathway. Front Cell Dev Biol 2021;9:638477. [PMID: 33968925 DOI: 10.3389/fcell.2021.638477] [Reference Citation Analysis]
34 Kai H, Doi M, Okada M, Yamada K, Iwabe H, Saito C, Yamagata K. Evaluation of the Validity of a Novel CKD Assessment Checklist Used in the Frontier of Renal Outcome Modifications in Japan Study. J Ren Nutr 2016;26:334-40. [PMID: 27085664 DOI: 10.1053/j.jrn.2016.02.010] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Sämann A, Wolf G. [Diabetic nephropathy]. Internist (Berl) 2012;53:1195-206. [PMID: 22961072 DOI: 10.1007/s00108-012-3129-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
36 Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12:2032-2045. [PMID: 28522654 DOI: 10.2215/cjn.11491116] [Cited by in Crossref: 515] [Cited by in F6Publishing: 278] [Article Influence: 103.0] [Reference Citation Analysis]
37 Shih CJ, Wu YL, Lo YH, Kuo SC, Tarng DC, Lin CC, Ou SM, Chen YT. Association of hypoglycemia with incident chronic kidney disease in patients with type 2 diabetes: a nationwide population-based study. Medicine (Baltimore) 2015;94:e771. [PMID: 25906112 DOI: 10.1097/MD.0000000000000771] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
38 Jendle J, Ericsson Å, Hunt B, Valentine WJ, Pollock RF. Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. Diabetes Ther 2018;9:87-99. [PMID: 29204855 DOI: 10.1007/s13300-017-0344-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
39 Quiroga B, Arroyo D, de Arriba G. Present and future in the treatment of diabetic kidney disease. J Diabetes Res 2015;2015:801348. [PMID: 25945357 DOI: 10.1155/2015/801348] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
40 Bächle C, Lange K, Stahl-Pehe A, Castillo K, Scheuing N, Holl RW, Giani G, Rosenbauer J. Symptoms of Eating Disorders and Depression in Emerging Adults with Early-Onset, Long-Duration Type 1 Diabetes and Their Association with Metabolic Control. PLoS One 2015;10:e0131027. [PMID: 26121155 DOI: 10.1371/journal.pone.0131027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
41 Khan UA, Garg AX, Parikh CR, Coca SG. Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis. PLoS One 2013;8:e71784. [PMID: 24009665 DOI: 10.1371/journal.pone.0071784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
42 Kim C, Cleary PA, Cowie CC, Braffett BH, Dunn RL, Larkin ME, Gatcomb PM, Wessells HB, Nathan DM, Sarma AV; DCCT/EDIC Research Group. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care 2014;37:701-8. [PMID: 24170751 DOI: 10.2337/dc13-1746] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
43 Afkarian M. Diabetic kidney disease in children and adolescents. Pediatr Nephrol 2015;30:65-74; quiz 70-1. [PMID: 24643739 DOI: 10.1007/s00467-014-2796-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
44 Basu A, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, Lopes-Virella MF, Garvey WT, Schade DS, Wood J, Alaupovic P, Lyons TJ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. J Lipid Res 2018;59:872-83. [PMID: 29576550 DOI: 10.1194/jlr.P080143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
45 DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014;2:793-800. [PMID: 25043685 DOI: 10.1016/S2213-8587(14)70155-X] [Cited by in Crossref: 100] [Cited by in F6Publishing: 47] [Article Influence: 12.5] [Reference Citation Analysis]
46 Chowdhury NH, Reaz MBI, Haque F, Ahmad S, Ali SHM, A Bakar AA, Bhuiyan MAS. Performance Analysis of Conventional Machine Learning Algorithms for Identification of Chronic Kidney Disease in Type 1 Diabetes Mellitus Patients. Diagnostics (Basel) 2021;11:2267. [PMID: 34943504 DOI: 10.3390/diagnostics11122267] [Reference Citation Analysis]
47 Gabriel EE, Gilbert PB. Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy. Biostatistics 2014;15:251-65. [PMID: 24337534 DOI: 10.1093/biostatistics/kxt055] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
48 Riera M, Márquez E, Clotet S, Gimeno J, Roca-Ho H, Lloreta J, Juanpere N, Batlle D, Pascual J, Soler MJ. Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse. PLoS One 2014;9:e84683. [PMID: 24400109 DOI: 10.1371/journal.pone.0084683] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
49 Bassi R, Fornoni A, Doria A, Fiorina P. CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease. Diabetologia 2016;59:21-9. [PMID: 26409459 DOI: 10.1007/s00125-015-3766-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
50 Fernandez-Fernandez B, Ortiz A, Gomez-Guerrero C, Egido J. Therapeutic approaches to diabetic nephropathy--beyond the RAS. Nat Rev Nephrol 2014;10:325-46. [PMID: 24802062 DOI: 10.1038/nrneph.2014.74] [Cited by in Crossref: 118] [Cited by in F6Publishing: 103] [Article Influence: 14.8] [Reference Citation Analysis]
51 Bae J, Won YJ, Lee BW. Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD). Life (Basel) 2021;11:224. [PMID: 33802211 DOI: 10.3390/life11030224] [Reference Citation Analysis]
52 Tuttle KR. Diabetic Kidney Disease: A Call to Action: Preface. Diabetes Spectr 2015;28:158-60. [PMID: 26300606 DOI: 10.2337/diaspect.28.3.158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Jardine MJ, Kasiske B, Adu D, Alrukhaimi M, Ashuntantang GE, Basnet S, Chailimpamontree W, Craig JC, O'Donoghue DJ, Perkovic V, Powe NR, Roberts CJ, Suzuki Y, Tanaka T, Uhlig K. Closing the gap between evidence and practice in chronic kidney disease. Kidney Int Suppl (2011) 2017;7:114-21. [PMID: 30675425 DOI: 10.1016/j.kisu.2017.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
54 de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge SN, Marx N, McGuire DK, Orchard TJ, Zinman B, Eckel RH. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 2014;37:2843-63. [PMID: 25114297 DOI: 10.2337/dc14-1720] [Cited by in Crossref: 221] [Cited by in F6Publishing: 202] [Article Influence: 27.6] [Reference Citation Analysis]
55 Molitch ME, Gao X, Bebu I, de Boer IH, Lachin J, Paterson A, Perkins B, Saenger AK, Steffes M, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes: The DCCT/EDIC Experience. Clin J Am Soc Nephrol 2019;14:854-61. [PMID: 31123181 DOI: 10.2215/CJN.14831218] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
56 Rodríguez-Pérez MD, López-Villodres JA, Arrebola MM, Martín-Aurioles E, Fernández-Prior Á, Bermúdez-Oria A, Ríos MC, De La Cruz JP, González-Correa JA. Nephroprotective Effect of the Virgin Olive Oil Polyphenol Hydroxytyrosol in Type 1-like Experimental Diabetes Mellitus: Relationships with Its Antioxidant Effect. Antioxidants (Basel) 2021;10:1783. [PMID: 34829654 DOI: 10.3390/antiox10111783] [Reference Citation Analysis]
57 Testa R, Bonfigli AR, Prattichizzo F, La Sala L, De Nigris V, Ceriello A. The "Metabolic Memory" Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. Nutrients 2017;9:E437. [PMID: 28452927 DOI: 10.3390/nu9050437] [Cited by in Crossref: 99] [Cited by in F6Publishing: 82] [Article Influence: 19.8] [Reference Citation Analysis]
58 Jindal A, Garcia-Touza M, Jindal N, Whaley-Connell A, Sowers JR. Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives. Endocrinol Metab Clin North Am. 2013;42:789-808. [PMID: 24286950 DOI: 10.1016/j.ecl.2013.06.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
59 Mauer M, Doria A. Uric Acid and Diabetic Nephropathy Risk. Contrib Nephrol 2018;192:103-9. [PMID: 29393137 DOI: 10.1159/000484284] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
60 Rojas-Rivera J, Ortiz A, Egido J. Antioxidants in kidney diseases: the impact of bardoxolone methyl. Int J Nephrol 2012;2012:321714. [PMID: 22701794 DOI: 10.1155/2012/321714] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
61 Ho K, McKnight AJ. The changing landscape of diabetic kidney disease: new reflections on phenotype, classification, and disease progression to influence future investigative studies and therapeutic trials. Adv Chronic Kidney Dis 2014;21:256-9. [PMID: 24780452 DOI: 10.1053/j.ackd.2014.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
62 Mundinger TO, Mei Q, Foulis AK, Fligner CL, Hull RL, Taborsky GJ Jr. Human Type 1 Diabetes Is Characterized by an Early, Marked, Sustained, and Islet-Selective Loss of Sympathetic Nerves. Diabetes. 2016;65:2322-2330. [PMID: 27207540 DOI: 10.2337/db16-0284] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
63 Drawz PE, Rosenberg ME. Slowing progression of chronic kidney disease. Kidney Int Suppl (2011) 2013;3:372-6. [PMID: 25019022 DOI: 10.1038/kisup.2013.80] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
64 Modafferi S, Ries M, Calabrese V, Schmitt CP, Nawroth P, Kopf S, Peters V. Clinical Trials on Diabetic Nephropathy: A Cross-Sectional Analysis. Diabetes Ther 2019;10:229-43. [PMID: 30617943 DOI: 10.1007/s13300-018-0551-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Zheng X, Soroush F, Long J, Hall ET, Adishesha PK, Bhattacharya S, Kiani MF, Bhalla V. Murine glomerular transcriptome links endothelial cell-specific molecule-1 deficiency with susceptibility to diabetic nephropathy. PLoS One 2017;12:e0185250. [PMID: 28934365 DOI: 10.1371/journal.pone.0185250] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
66 de Boer IH, Sachs MC, Cleary PA, Hoofnagle AN, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD; Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group. Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J Clin Endocrinol Metab 2012;97:4780-8. [PMID: 22990096 DOI: 10.1210/jc.2012-2852] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
67 Bjornstad P, McQueen RB, Snell-Bergeon JK, Cherney D, Pyle L, Perkins B, Rewers M, Maahs DM. Fasting blood glucose--a missing variable for GFR-estimation in type 1 diabetes? PLoS One 2014;9:e96264. [PMID: 24781861 DOI: 10.1371/journal.pone.0096264] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
68 Burke SD, Sherr D, Lipman RD. Partnering with diabetes educators to improve patient outcomes. Diabetes Metab Syndr Obes. 2014;7:45-53. [PMID: 24550679 DOI: 10.2147/dmso.s40036] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
69 Cooper ME. Diabetes: treating diabetic nephropathy-still an unresolved issue. Nat Rev Endocrinol. 2012;8:515-516. [PMID: 22825399 DOI: 10.1038/nrendo.2012.125] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
70 Reddy MA, Park JT, Natarajan R. Epigenetic modifications and diabetic nephropathy. Kidney Res Clin Pract 2012;31:139-50. [PMID: 26894019 DOI: 10.1016/j.krcp.2012.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
71 Hoosen MZ, Paruk IM, Pirie FJ, Motala AA. Trends in glycaemic control and morbidity over 10 years in patients with type 1 diabetes mellitus at Inkosi Albert Luthuli Central Hospital. Journal of Endocrinology, Metabolism and Diabetes of South Africa 2020;25:36-43. [DOI: 10.1080/16089677.2020.1748321] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Baker NL, Hunt KJ, Stevens DR, Jarai G, Rosen GD, Klein RL, Virella G, Lopes-Virella MF; DCCT/EDIC Research Group. Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care 2018;41:128-35. [PMID: 29118060 DOI: 10.2337/dc17-0867] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
73 Hsu RK, Hsu CY. Temporal trends in prevalence of CKD: the glass is half full and not half empty. Am J Kidney Dis 2013;62:214-6. [PMID: 23883656 DOI: 10.1053/j.ajkd.2013.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
74 Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, Bakris G, Gutiérrez OM, Hebert LA, Ix JH, Lea J, Lipkowitz MS, Norris K, Ploth D, Pogue VA, Rostand SG, Siew ED, Sika M, Tisher CC, Toto R, Wright JT Jr, Wyatt C, Hsu CY. BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol 2017;28:671-7. [PMID: 27516235 DOI: 10.1681/ASN.2016030326] [Cited by in Crossref: 52] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
75 Ortiz A, Abiose A, Bichet DG, Cabrera G, Charrow J, Germain DP, Hopkin RJ, Jovanovic A, Linhart A, Maruti SS, Mauer M, Oliveira JP, Patel MR, Politei J, Waldek S, Wanner C, Yoo HW, Warnock DG. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet 2016;53:495-502. [PMID: 26993266 DOI: 10.1136/jmedgenet-2015-103486] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 8.8] [Reference Citation Analysis]
76 Piscitelli P, Viazzi F, Fioretto P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Pontremoli R, De Cosmo S. Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Sci Rep 2017;7:3313. [PMID: 28607417 DOI: 10.1038/s41598-017-03551-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
77 Kuo IC, Lin HY, Niu SW, Hwang DY, Lee JJ, Tsai JC, Hung CC, Hwang SJ, Chen HC. Glycated Hemoglobin and Outcomes in Patients with Advanced Diabetic Chronic Kidney Disease. Sci Rep 2016;6:20028. [PMID: 26818011 DOI: 10.1038/srep20028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
78 Gubitosi-Klug RA; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care 2014;37:44-9. [PMID: 24356597 DOI: 10.2337/dc13-2148] [Cited by in Crossref: 75] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
79 Ko YA, Susztak K. Epigenomics: the science of no-longer-junk DNA. Why study it in chronic kidney disease? Semin Nephrol 2013;33:354-62. [PMID: 24011577 DOI: 10.1016/j.semnephrol.2013.05.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
80 Cleary PA, Braffett BH, Orchard T, Lyons TJ, Maynard J, Cowie C, Gubitosi-Klug RA, Way J, Anderson K, Barnie A, Villavicencio S; DCCT/EDIC Research Group. Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Technol Ther 2013;15:466-74. [PMID: 23882708 DOI: 10.1089/dia.2012.0316] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
81 Roshandel D, Chen Z, Canty AJ, Bull SB, Natarajan R, Paterson AD; DCCT/EDIC Research Group. DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes. Clin Epigenetics 2020;12:52. [PMID: 32248841 DOI: 10.1186/s13148-020-00840-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
82 Bjornstad P, Snell-Bergeon JK, Rewers M, Jalal D, Chonchol MB, Johnson RJ, Maahs DM. Early diabetic nephropathy: a complication of reduced insulin sensitivity in type 1 diabetes. Diabetes Care. 2013;36:3678-3683. [PMID: 24026551 DOI: 10.2337/dc13-0631] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 5.2] [Reference Citation Analysis]
83 Xu M, Bi Y, Huang Y, Xie L, Hao M, Zhao Z, Xu Y, Lu J, Chen Y, Sun Y, Qi L, Wang W, Ning G. Type 2 Diabetes, Diabetes Genetic Score and Risk of Decreased Renal Function and Albuminuria: A Mendelian Randomization Study. EBioMedicine 2016;6:162-70. [PMID: 27211558 DOI: 10.1016/j.ebiom.2016.02.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
84 Caramori ML, Kim Y, Natarajan R, Moore JH, Rich SS, Mychaleckyj JC, Kuriyama R, Kirkpatrick D, Mauer M. Differential Response to High Glucose in Skin Fibroblasts of Monozygotic Twins Discordant for Type 1 Diabetes. J Clin Endocrinol Metab 2015;100:E883-9. [PMID: 25901990 DOI: 10.1210/jc.2014-4467] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
85 de Boer IH, Afkarian M, Rue TC, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2014;25:2342-50. [PMID: 24925722 DOI: 10.1681/ASN.2013091004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
86 Satirapoj B, Adler SG. Prevalence and Management of Diabetic Nephropathy in Western Countries. Kidney Dis (Basel) 2015;1:61-70. [PMID: 27536666 DOI: 10.1159/000382028] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
87 Fukuda A, Minakawa A, Kikuchi M, Sato Y, Nagatomo M, Nakamura S, Mizoguchi T, Fukunaga N, Shibata H, Naik AS, Wiggins RC, Fujimoto S. Urinary podocyte mRNAs precede microalbuminuria as a progression risk marker in human type 2 diabetic nephropathy. Sci Rep 2020;10:18209. [PMID: 33097787 DOI: 10.1038/s41598-020-75320-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, Backlund JY, Lachin JM; Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45-53. [PMID: 25562265 DOI: 10.1001/jama.2014.16107] [Cited by in Crossref: 297] [Cited by in F6Publishing: 227] [Article Influence: 42.4] [Reference Citation Analysis]
89 Umeukeje EM, Young BA. Genetics and ESKD Disparities in African Americans. Am J Kidney Dis 2019;74:811-21. [PMID: 31606237 DOI: 10.1053/j.ajkd.2019.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
90 Molitch ME. Diabetic Kidney Disease: Much Progress, But Still More to Do. Diabetes Spectr 2015;28:154-6. [PMID: 26300605 DOI: 10.2337/diaspect.28.3.154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
91 Qi W, Li Q, Gordin D, King GL. Preservation of renal function in chronic diabetes by enhancing glomerular glucose metabolism. J Mol Med (Berl) 2018;96:373-81. [PMID: 29574544 DOI: 10.1007/s00109-018-1630-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
92 Satirapoj B. Sodium-Glucose Cotransporter 2 Inhibitors with Renoprotective Effects. Kidney Dis (Basel) 2017;3:24-32. [PMID: 28785561 DOI: 10.1159/000471765] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
93 Laursen JC, Clemmensen KKB, Hansen CS, Diaz LJ, Bordino M, Groop PH, Frimodt-Moller M, Bernardi L, Rossing P. Persons with type 1 diabetes have low blood oxygen levels in the supine and standing body positions. BMJ Open Diabetes Res Care 2021;9:e001944. [PMID: 34059524 DOI: 10.1136/bmjdrc-2020-001944] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Copur S, Rossing P, Afsar B, Sag AA, Siriopol D, Kuwabara M, Ortiz A, Kanbay M. A primer on metabolic memory: why existing diabesity treatments fail. Clin Kidney J 2021;14:756-67. [PMID: 34512957 DOI: 10.1093/ckj/sfaa143] [Reference Citation Analysis]
95 Mundinger TO, Taborsky GJ Jr. Early sympathetic islet neuropathy in autoimmune diabetes: lessons learned and opportunities for investigation. Diabetologia 2016;59:2058-67. [PMID: 27342407 DOI: 10.1007/s00125-016-4026-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
96 Yokoyama H, Araki SI, Kawai K, Yamazaki K, Tomonaga O, Shirabe SI, Maegawa H. Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46). BMJ Open Diabetes Res Care 2018;6:e000521. [PMID: 29892340 DOI: 10.1136/bmjdrc-2018-000521] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
97 Nickerson HD, Dutta S. JDRF perspective: bridging the gap-translational research to prevent progression of diabetic nephropathy. Semin Nephrol 2012;32:512-6. [PMID: 23062993 DOI: 10.1016/j.semnephrol.2012.07.015] [Reference Citation Analysis]
98 Srinivasan R, Gokulakrishnan K, Lourdusamy R, Nilavan E, Balaji N. Prevalence of rapid renal decliner phenotype in south India: A retrospective study. Diabetes Metab Syndr 2021;16:102334. [PMID: 34920201 DOI: 10.1016/j.dsx.2021.102334] [Reference Citation Analysis]
99 Chen Y, Lee K, Ni Z, He JC. Diabetic Kidney Disease: Challenges, Advances, and Opportunities. Kidney Dis (Basel) 2020;6:215-25. [PMID: 32903946 DOI: 10.1159/000506634] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
100 Nakamura T, Fujikura J, Anazawa T, Ito R, Ogura M, Okajima H, Uemoto S, Inagaki N. Long-term outcome of islet transplantation on insulin-dependent diabetes mellitus: An observational cohort study. J Diabetes Investig 2020;11:363-72. [PMID: 31390159 DOI: 10.1111/jdi.13128] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
101 Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28. [PMID: 24475922 DOI: 10.1186/1475-2840-13-28] [Cited by in Crossref: 282] [Cited by in F6Publishing: 264] [Article Influence: 35.3] [Reference Citation Analysis]
102 Montagud-Marrahi E, Molina-Andújar A, Pané A, Ramírez-Bajo MJ, Amor A, Esmatjes E, Ferrer J, Musquera M, Diekmann F, Ventura-Aguiar P. Outcomes of pancreas transplantation in older diabetic patients. BMJ Open Diabetes Res Care 2020;8:e000916. [PMID: 32144128 DOI: 10.1136/bmjdrc-2019-000916] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
103 Perkins BA, Bebu I, de Boer IH, Molitch M, Tamborlane W, Lorenzi G, Herman W, White NH, Pop-Busui R, Paterson AD, Orchard T, Cowie C, Lachin JM; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care 2019;42:883-90. [PMID: 30833370 DOI: 10.2337/dc18-2062] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
104 Kato M, Natarajan R. Diabetic nephropathy--emerging epigenetic mechanisms. Nat Rev Nephrol 2014;10:517-30. [PMID: 25003613 DOI: 10.1038/nrneph.2014.116] [Cited by in Crossref: 175] [Cited by in F6Publishing: 171] [Article Influence: 21.9] [Reference Citation Analysis]
105 Bjornstad P, Maahs DM. Diabetes Complications in Childhood Diabetes-New Biomarkers and Technologies. Curr Pediatr Rep 2015;3:177-86. [PMID: 26425403 DOI: 10.1007/s40124-015-0081-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
106 de Boer IH; DCCT/EDIC Research Group. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014;37:24-30. [PMID: 24356594 DOI: 10.2337/dc13-2113] [Cited by in Crossref: 147] [Cited by in F6Publishing: 109] [Article Influence: 21.0] [Reference Citation Analysis]
107 Bjornstad P, Costacou T, Miller RG, Maahs DM, Rewers MJ, Orchard TJ, Snell-Bergeon JK. Predictors of early renal function decline in adults with Type 1 diabetes: the Coronary Artery Calcification in Type 1 Diabetes and the Pittsburgh Epidemiology of Diabetes Complications studies. Diabet Med 2017;34:1532-40. [PMID: 28734104 DOI: 10.1111/dme.13430] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
108 Skupien J, Warram JH, Smiles A, Galecki A, Stanton RC, Krolewski AS. Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria. J Am Soc Nephrol. 2014;25:2916-2925. [PMID: 24904086 DOI: 10.1681/asn.2013091002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
109 Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto P, Vecchio M, Craig JC, Strippoli GF. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 2017;6:CD010137. [PMID: 28594069 DOI: 10.1002/14651858.CD010137.pub2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
110 Bjerre-Christensen T, Winther SA, Tofte N, Theilade S, Ahluwalia TS, Lajer M, Hansen TW, Rossing P, Hansen CS. Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes. BMJ Open Diabetes Res Care 2021;9:e002289. [PMID: 34645614 DOI: 10.1136/bmjdrc-2021-002289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
111 Downs CA, Faulkner MS. Toxic stress, inflammation and symptomatology of chronic complications in diabetes. World J Diabetes 2015; 6(4): 554-565 [PMID: 25987953 DOI: 10.4239/wjd.v6.i4.554] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
112 Fujihara K, Sone H. Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus. Ann Vasc Dis 2018;11:2-14. [PMID: 29682103 DOI: 10.3400/avd.ra.17-00109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
113 Aiello LP, Sun W, Das A, Gangaputra S, Kiss S, Klein R, Cleary PA, Lachin JM, Nathan DM; DCCT/EDIC Research Group. Intensive diabetes therapy and ocular surgery in type 1 diabetes. N Engl J Med 2015;372:1722-33. [PMID: 25923552 DOI: 10.1056/NEJMoa1409463] [Cited by in Crossref: 52] [Cited by in F6Publishing: 27] [Article Influence: 7.4] [Reference Citation Analysis]
114 Baldwin D, Apel J. Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes. Curr Diab Rep 2013;13:114-20. [PMID: 23090580 DOI: 10.1007/s11892-012-0339-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
115 Guja C, Miulescu RD. Renoprotective Effects of SGLT2 Inhibitors. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 2019;26:95-8. [DOI: 10.2478/rjdnmd-2019-0010] [Reference Citation Analysis]
116 Bjornstad P, Cherney DZ, Snell-Bergeon JK, Pyle L, Rewers M, Johnson RJ, Maahs DM. Rapid GFR decline is associated with renal hyperfiltration and impaired GFR in adults with Type 1 diabetes. Nephrol Dial Transplant 2015;30:1706-11. [PMID: 26050268 DOI: 10.1093/ndt/gfv121] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
117 Nordheim E, Geir Jenssen T. Chronic kidney disease in patients with diabetes mellitus. Endocr Connect 2021;10:R151-9. [PMID: 33830068 DOI: 10.1530/EC-21-0097] [Reference Citation Analysis]
118 Xu L, Natarajan R, Chen Z. Epigenetic Risk Profile of Diabetic Kidney Disease in High-Risk Populations. Curr Diab Rep 2019;19:9. [PMID: 30730019 DOI: 10.1007/s11892-019-1129-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
119 Matejko B, Cyganek K, Katra B, Galicka-Latala D, Grzanka M, Malecki MT, Klupa T. Insulin pump therapy is equally effective and safe in elderly and young type 1 diabetes patients. Rev Diabet Stud 2011;8:254-8. [PMID: 22189548 DOI: 10.1900/RDS.2011.8.254] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
120 Tokutsu A, Okada Y, Torimoto K, Tanaka Y. Relationship between glycemic intraday variations evaluated in continuous glucose monitoring and HbA1c variability in type 2 diabetes: pilot study. Diabetol Metab Syndr 2021;13:45. [PMID: 33858481 DOI: 10.1186/s13098-021-00663-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Hering BJ, Bridges ND, Eggerman TL, Ricordi C; Clinical Islet Transplantation Consortium. Comment on Harlan. Islet Transplantation for Hypoglycemia Unawareness/Severe Hypoglycemia: Caveat Emptor. Diabetes Care 2016;39:1072-1074. Diabetes Care 2017;40:e111-2. [PMID: 28733382 DOI: 10.2337/dc16-2691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Nawroth P, Nitschmann S. [Improvement of glomerular filtration rate by intensified insulin therapy : the DCCT and EDIC studies]. Internist (Berl) 2012;53:1376-8. [PMID: 23069781 DOI: 10.1007/s00108-012-3161-z] [Reference Citation Analysis]
123 Shayman JA. Challenges and opportunities in the development of therapeutics for chronic kidney disease. Transl Res 2015;165:482-7. [PMID: 25218118 DOI: 10.1016/j.trsl.2014.08.002] [Reference Citation Analysis]
124 Distiller LA. Why do some patients with type 1 diabetes live so long? World J Diabetes 2014; 5(3): 282-287 [PMID: 24936249 DOI: 10.4239/wjd.v5.i3.282] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
125 Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig 2017;8:6-18. [PMID: 27181363 DOI: 10.1111/jdi.12533] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
126 Ku E, Glidden DV, Johansen KL, Sarnak M, Tighiouart H, Grimes B, Hsu CY. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney Int 2015;87:1055-60. [PMID: 25493952 DOI: 10.1038/ki.2014.376] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
127 Hung AM, Roumie CL, Greevy RA, Grijalva CG, Liu X, Murff HJ, Ikizler TA, Griffin MR. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline. Clin J Am Soc Nephrol 2016;11:2177-85. [PMID: 27827311 DOI: 10.2215/CJN.02630316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
128 Ba Aqeel S, Ye M, Wysocki J, Sanchez A, Khattab A, Lores E, Rademaker A, Gao X, Bebu I, Nelson RG, Molitch M, Batlle D; Diabetes Control, Complications Trial (DCCT)/Epidemiology of Diabetes Interventions, Complications (EDIC) Study. Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus. Physiol Rep 2019;7:e14242. [PMID: 31605461 DOI: 10.14814/phy2.14242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
129 Thomas B, Wulf S, Bikbov B, Perico N, Cortinovis M, Courville de Vaccaro K, Flaxman A, Peterson H, Delossantos A, Haring D, Mehrotra R, Himmelfarb J, Remuzzi G, Murray C, Naghavi M. Maintenance Dialysis throughout the World in Years 1990 and 2010. J Am Soc Nephrol 2015;26:2621-33. [PMID: 26209712 DOI: 10.1681/ASN.2014101017] [Cited by in Crossref: 114] [Cited by in F6Publishing: 52] [Article Influence: 16.3] [Reference Citation Analysis]
130 Bjornstad P, Karger AB, Maahs DM. Measured GFR in Routine Clinical Practice-The Promise of Dried Blood Spots. Adv Chronic Kidney Dis 2018;25:76-83. [PMID: 29499891 DOI: 10.1053/j.ackd.2017.09.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
131 Chatzikyrkou C, Haller H. Diabetes: hyperfiltration-a risk factor for nephropathy in T1DM? Nat Rev Endocrinol 2012;8:385-6. [PMID: 22525729 DOI: 10.1038/nrendo.2012.63] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
132 Itoh H, Kurihara I, Miyashita K, Tanaka M. Clinical significance of 'cardiometabolic memory': a systematic review of randomized controlled trials. Hypertens Res 2017;40:526-34. [PMID: 28100921 DOI: 10.1038/hr.2016.192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
133 Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015;38:954-962. [PMID: 25998286 DOI: 10.2337/dc15-0184] [Cited by in Crossref: 130] [Cited by in F6Publishing: 102] [Article Influence: 18.6] [Reference Citation Analysis]
134 Lachin JM, Nathan DM; DCCT/EDIC Research Group. Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care 2021:dc203097. [PMID: 34548284 DOI: 10.2337/dc20-3097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
135 Viana LV, Gomes MB, Zajdenverg L, Pavin EJ, Azevedo MJ; Brazilian Type 1 Diabetes Study Group. Interventions to improve patients' compliance with therapies aimed at lowering glycated hemoglobin (HbA1c) in type 1 diabetes: systematic review and meta-analyses of randomized controlled clinical trials of psychological, telecare, and educational interventions. Trials 2016;17:94. [PMID: 26888087 DOI: 10.1186/s13063-016-1207-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
136 Perco P, Pena M, Heerspink HJL, Mayer G; BEAt-DKD Consortium. Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice? Kidney Int Rep 2019;4:212-21. [PMID: 30775618 DOI: 10.1016/j.ekir.2018.12.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
137 Holt SK, Lopushnyan N, Hotaling J, Sarma AV, Dunn RL, Cleary PA, Braffett BH, Gatcomb P, Martin C, Herman WH, Wessells H; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Prevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT/EDIC. J Clin Endocrinol Metab 2014;99:E1655-60. [PMID: 25013994 DOI: 10.1210/jc.2014-1317] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
138 Kato M, Natarajan R. MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets. Ann N Y Acad Sci 2015;1353:72-88. [PMID: 25877817 DOI: 10.1111/nyas.12758] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 14.4] [Reference Citation Analysis]
139 Mottl AK, Buse JB, Ismail-Beigi F, Sigal RJ, Pedley CF, Papademetriou V, Simmons DL, Katz L, Mychaleckyj JC, Craven TE. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. Clin J Am Soc Nephrol 2018;13:1693-702. [PMID: 30361335 DOI: 10.2215/CJN.06200518] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
140 Chen Z, Miao F, Braffett BH, Lachin JM, Zhang L, Wu X, Roshandel D, Carless M, Li XA, Tompkins JD, Kaddis JS, Riggs AD, Paterson AD, Natarajan R; DCCT/EDIC Study Group. DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes. Nat Metab 2020;2:744-62. [PMID: 32694834 DOI: 10.1038/s42255-020-0231-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
141 MacIsaac RJ, Jerums G, Ekinci EI. Glycemic Control as Primary Prevention for Diabetic Kidney Disease. Adv Chronic Kidney Dis 2018;25:141-8. [PMID: 29580578 DOI: 10.1053/j.ackd.2017.11.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
142 Bera A, Das F, Ghosh-Choudhury N, Mariappan MM, Kasinath BS, Ghosh Choudhury G. Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion. Am J Physiol Cell Physiol 2017;313:C430-47. [PMID: 28701356 DOI: 10.1152/ajpcell.00081.2017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
143 Tang SC, Chan GC, Lai KN. Recent advances in managing and understanding diabetic nephropathy. F1000Res. 2016;5:pii: F1000 Faculty Rev-1044. [PMID: 27303648 DOI: 10.12688/f1000research.7693.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
144 Krolewski AS, Bonventre JV. High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline. Semin Nephrol 2012;32:407-14. [PMID: 23062980 DOI: 10.1016/j.semnephrol.2012.07.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
145 Kim C, Pan Y, Braffett BH, Arends VL, Steffes MW, Wessells H, Sarma AV; DCCT/EDIC Research Group. Anti-Müllerian hormone and its relationships with subclinical cardiovascular disease and renal disease in a longitudinal cohort study of women with type 1 diabetes. Womens Midlife Health 2017;3:5. [PMID: 30766706 DOI: 10.1186/s40695-017-0023-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
146 Hyllienmark L, Alstrand N, Jonsson B, Ludvigsson J, Cooray G, Wahlberg-Topp J. Early electrophysiological abnormalities and clinical neuropathy: a prospective study in patients with type 1 diabetes. Diabetes Care. 2013;36:3187-3194. [PMID: 23723354 DOI: 10.2337/dc12-2226] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
147 Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, Lorenzi G, Zinman B; DCCT/EDIC Research Group. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 2013;62:3976-86. [PMID: 24264395 DOI: 10.2337/db13-1093] [Cited by in Crossref: 142] [Cited by in F6Publishing: 111] [Article Influence: 17.8] [Reference Citation Analysis]
148 Solis-Herrera C, Triplitt CL, Lynch JL. Nephropathy in youth and young adults with type 2 diabetes. Curr Diab Rep 2014;14:456. [PMID: 24398660 DOI: 10.1007/s11892-013-0456-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
149 Gohda T, Tomino Y. Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors. Curr Diab Rep 2013;13:560-6. [PMID: 23657763 DOI: 10.1007/s11892-013-0385-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
150 Ku E, Lipkowitz MS, Appel LJ, Parsa A, Gassman J, Glidden DV, Smogorzewski M, Hsu CY. Strict blood pressure control associates with decreased mortality risk by APOL1 genotype. Kidney Int 2017;91:443-50. [PMID: 27927600 DOI: 10.1016/j.kint.2016.09.033] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
151 Hu W, Hao H, Yu W, Wu X, Zhou H. Association of elevated glycosylated hemoglobin A1c with hyperfiltration in a middle-aged and elderly Chinese population with prediabetes or newly diagnosed diabetes: a cross-sectional study. BMC Endocr Disord. 2015;15:47. [PMID: 26363801 DOI: 10.1186/s12902-015-0043-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
152 Lee CL, Li TC, Lin SY, Wang JS, Lee IT, Tseng LN, Song YM, Tsai SF, Sheu WH. Dynamic and dual effects of glycated hemoglobin on estimated glomerular filtration rate in type 2 diabetic outpatients. Am J Nephrol 2013;38:19-26. [PMID: 23817017 DOI: 10.1159/000351803] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
153 Schmidt BM. [Therapeutic strategies to prevent chronic kidney disease progression]. Internist (Berl) 2012;53:810-6. [PMID: 22714581 DOI: 10.1007/s00108-011-3012-3] [Reference Citation Analysis]
154 Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014;CD009122. [PMID: 24526393 DOI: 10.1002/14651858.cd009122.pub2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 9.1] [Reference Citation Analysis]
155 Salinero-Fort MA, San Andrés-Rebollo FJ, de Burgos-Lunar C, Gómez-Campelo P, Chico-Moraleja RM, López de Andrés A, Jiménez-García R; MADIABETES Group. Five-year incidence of chronic kidney disease (stage 3-5) and associated risk factors in a Spanish cohort: the MADIABETES Study. PLoS One 2015;10:e0122030. [PMID: 25856231 DOI: 10.1371/journal.pone.0122030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
156 Jermendy G. Vascular memory: can we broaden the concept of the metabolic memory? Cardiovasc Diabetol 2012;11:44. [PMID: 22545680 DOI: 10.1186/1475-2840-11-44] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
157 Satirapoj B, Adler SG. Comprehensive approach to diabetic nephropathy. Kidney Res Clin Pract 2014;33:121-31. [PMID: 26894033 DOI: 10.1016/j.krcp.2014.08.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
158 Tanamas SK, Saulnier PJ, Fufaa GD, Wheelock KM, Weil EJ, Hanson RL, Knowler WC, Bennett PH, Nelson RG. Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial. Diabetes Care 2016;39:2004-10. [PMID: 27612501 DOI: 10.2337/dc16-0795] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
159 Yoon HJ, Lee YH, Kim SR, Rim TH, Lee EY, Kang ES, Cha BS, Lee HC, Lee BW. Glycated albumin and the risk of micro- and macrovascular complications in subjects with type 1 diabetes. Cardiovasc Diabetol. 2015;14:53. [PMID: 25975731 DOI: 10.1186/s12933-015-0219-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
160 Block TJ, Batu D, Cooper ME. Recent advances in the pharmacotherapeutic management of diabetic kidney disease. Expert Opin Pharmacother 2022;:1-13. [PMID: 35522659 DOI: 10.1080/14656566.2022.2054699] [Reference Citation Analysis]
161 Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M; PERL Study Group. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. N Engl J Med 2020;382:2493-503. [PMID: 32579810 DOI: 10.1056/NEJMoa1916624] [Cited by in Crossref: 72] [Cited by in F6Publishing: 27] [Article Influence: 36.0] [Reference Citation Analysis]
162 Cohen JB, Bloom RD, Reese PP, Porrett PM, Forde KA, Sawinski DL. National outcomes of kidney transplantation from deceased diabetic donors. Kidney Int 2015. [PMID: 26489026 DOI: 10.1038/ki.2015.325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
163 Orchard TJ, Backlund JC, Costacou T, Cleary P, Lopes-Virella M, Levy AP, Lachin JM; DCCT/EDIC Research Group. Haptoglobin 2-2 genotype and the risk of coronary artery disease in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). J Diabetes Complications. 2016;30:1577-1584. [PMID: 27539884 DOI: 10.1016/j.jdiacomp.2016.07.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
164 Naimark DM, Grams ME, Matsushita K, Black C, Drion I, Fox CS, Inker LA, Ishani A, Jee SH, Kitamura A, Lea JP, Nally J, Peralta CA, Rothenbacher D, Ryu S, Tonelli M, Yatsuya H, Coresh J, Gansevoort RT, Warnock DG, Woodward M, de Jong PE; CKD Prognosis Consortium. Past Decline Versus Current eGFR and Subsequent Mortality Risk. J Am Soc Nephrol 2016;27:2456-66. [PMID: 26657865 DOI: 10.1681/ASN.2015060688] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
165 Lovrenčić MV, Biljak VR, Blaslov K, Božičević S, Duvnjak LS. Impact of creatinine methodology on glomerular filtration rate estimation in diabetes. World J Diabetes 2017; 8(5): 222-229 [PMID: 28572883 DOI: 10.4239/wjd.v8.i5.222] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
166 Cardoso CRL, Leite NC, Salles GC, Ferreira MT, Salles GF. Aortic stiffness and ambulatory blood pressure as predictors of diabetic kidney disease: a competing risks analysis from the Rio de Janeiro Type 2 Diabetes Cohort Study. Diabetologia 2018;61:455-65. [PMID: 29063128 DOI: 10.1007/s00125-017-4484-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
167 Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, Freeman R, Green J, Huang E, Isaacs D, Kahan S, Leon J, Lyons SK, Peters AL, Prahalad P, Reusch JEB, Young-Hyman D, Das S, Kosiborod M; American Diabetes Association Professional Practice Committee., American Diabetes Association Professional Practice Committee:. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45:S175-84. [PMID: 34964873 DOI: 10.2337/dc22-S011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
168 Gnudi L. Podocytes and the struggle against glucose toxicity: new targets for treatment? Metabolism 2012;61:1051-4. [PMID: 22386941 DOI: 10.1016/j.metabol.2012.01.015] [Reference Citation Analysis]
169 Peeters MJ, van Zuilen AD, van den Brand JA, Bots ML, van Buren M, Ten Dam MA, Kaasjager KA, Ligtenberg G, Sijpkens YW, Sluiter HE, van de Ven PJ, Vervoort G, Vleming LJ, Blankestijn PJ, Wetzels JF. Nurse practitioner care improves renal outcome in patients with CKD. J Am Soc Nephrol 2014;25:390-8. [PMID: 24158983 DOI: 10.1681/ASN.2012121222] [Cited by in Crossref: 60] [Cited by in F6Publishing: 28] [Article Influence: 6.7] [Reference Citation Analysis]
170 Otani T, Yokoyama H, Ohashi Y, Uchigata Y. Improved incidence of end-stage renal disease of type 1 diabetes in Japan, from a hospital-based survey. BMJ Open Diabetes Res Care 2016;4:e000177. [PMID: 27110369 DOI: 10.1136/bmjdrc-2015-000177] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
171 Murphy D, McCulloch CE, Lin F, Banerjee T, Bragg-Gresham JL, Eberhardt MS, Morgenstern H, Pavkov ME, Saran R, Powe NR, Hsu CY; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Trends in Prevalence of Chronic Kidney Disease in the United States. Ann Intern Med 2016;165:473-81. [PMID: 27479614 DOI: 10.7326/M16-0273] [Cited by in Crossref: 244] [Cited by in F6Publishing: 130] [Article Influence: 40.7] [Reference Citation Analysis]
172 Guan G, Xie J, Dai Y, Han H. TFPI2 suppresses the interaction of TGF-β2 pathway regulators to promote endothelial-mesenchymal transition in diabetic nephropathy. J Biol Chem 2022;298:101725. [PMID: 35157852 DOI: 10.1016/j.jbc.2022.101725] [Reference Citation Analysis]
173 Urva S, Quinlan T, Landry J, Martin J, Loghin C. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet 2021;60:1049-59. [PMID: 33778934 DOI: 10.1007/s40262-021-01012-2] [Reference Citation Analysis]
174 Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, Griffin MR. Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control. Pharmacoepidemiol Drug Saf 2013;22:623-31. [PMID: 23592561 DOI: 10.1002/pds.3432] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
175 Colom C, Rull A, Sanchez-Quesada JL, Pérez A. Cardiovascular Disease in Type 1 Diabetes Mellitus: Epidemiology and Management of Cardiovascular Risk. J Clin Med 2021;10:1798. [PMID: 33924265 DOI: 10.3390/jcm10081798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
176 Gabriel EE, Sachs MC, Gilbert PB. Comparing and combining biomarkers as principal surrogates for time-to-event clinical endpoints. Stat Med 2015;34:381-95. [PMID: 25352131 DOI: 10.1002/sim.6349] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
177 Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 2014;10:88-103. [PMID: 24375052 DOI: 10.1038/nrneph.2013.272] [Cited by in Crossref: 117] [Cited by in F6Publishing: 104] [Article Influence: 13.0] [Reference Citation Analysis]
178 Skupien J, Warram JH, Niewczas MA, Gohda T, Malecki M, Mychaleckyj JC, Galecki AT, Krolewski AS. Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria. Diabetes Care 2014;37:2601-8. [PMID: 24898299 DOI: 10.2337/dc13-1983] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
179 Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM; DCCT/EDIC Research Group. Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care 2019;42:1284-9. [PMID: 30894365 DOI: 10.2337/dc18-1613] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
180 Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s? Diabetologia. 2012;55:2301-2306. [PMID: 22696035 DOI: 10.1007/s00125-012-2606-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
181 Fan X, Teliewubai J, Xiong J, Chi C, Lu Y, Zhu M, Zhang Y, Xu Y. Renal functional impairment in the elderly, the importance of fasting plasma glucose: the Northern Shanghai Study. Aging Clin Exp Res 2021;33:353-60. [PMID: 32200498 DOI: 10.1007/s40520-020-01527-x] [Reference Citation Analysis]
182 Maahs DM, Caramori L, Cherney DZ, Galecki AT, Gao C, Jalal D, Perkins BA, Pop-Busui R, Rossing P, Mauer M. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. Curr Diab Rep. 2013;13:550-559. [PMID: 23649945 DOI: 10.1007/s11892-013-0381-0] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 14.1] [Reference Citation Analysis]
183 Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int 2017;91:1300-11. [PMID: 28366227 DOI: 10.1016/j.kint.2016.10.046] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 19.2] [Reference Citation Analysis]
184 Triozzi JL, Parker Gregg L, Virani SS, Navaneethan SD. Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Res Care 2021;9:e002300. [PMID: 34312158 DOI: 10.1136/bmjdrc-2021-002300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. J Am Soc Nephrol 2017;28:2263-74. [PMID: 28465376 DOI: 10.1681/ASN.2016121372] [Cited by in Crossref: 40] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
186 Bouhanick B, Barigou M, Kantambadouno JB, Chamontin B. [Glycaemic control and complications of diabetes: what about?]. Presse Med 2013;42:849-54. [PMID: 23540378 DOI: 10.1016/j.lpm.2013.02.315] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
187 Allison SJ. Diabetes: Intensive glucose control in type 1 diabetes mellitus reduces risk of GFR loss. Nat Rev Endocrinol 2011;8:65. [PMID: 22143184 DOI: 10.1038/nrendo.2011.214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
188 Li SY, Huang PH, Tarng DC, Lin TP, Yang WC, Chang YH, Yang AH, Lin CC, Yang MH, Chen JW, Schmid-Schönbein GW, Chien S, Chu PH, Lin SJ. Four-and-a-Half LIM Domains Protein 2 Is a Coactivator of Wnt Signaling in Diabetic Kidney Disease. J Am Soc Nephrol 2015;26:3072-84. [PMID: 25855776 DOI: 10.1681/ASN.2014100989] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
189 Fradkin JE, Cowie CC, Hanlon MC, Rodgers GP. Celebrating 30 years of research accomplishments of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes 2013;62:3963-7. [PMID: 24264393 DOI: 10.2337/db13-1108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
190 Markó L, Mannaa M, Haschler TN, Krämer S, Gollasch M. Renoprotection: focus on TRPV1, TRPV4, TRPC6 and TRPM2. Acta Physiol (Oxf) 2017;219:589-612. [PMID: 28028935 DOI: 10.1111/apha.12828] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
191 Wu DC, Hester J, Nadig SN, Zhang W, Trzonkowski P, Gray D, Hughes S, Johnson P, Wood KJ. Ex vivo expanded human regulatory T cells can prolong survival of a human islet allograft in a humanized mouse model. Transplantation 2013;96:707-16. [PMID: 23917725 DOI: 10.1097/TP.0b013e31829fa271] [Cited by in Crossref: 56] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
192 Kato M, Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat Rev Nephrol 2019;15:327-45. [PMID: 30894700 DOI: 10.1038/s41581-019-0135-6] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 45.0] [Reference Citation Analysis]
193 Forbes A, Gallagher H. Chronic kidney disease in adults: assessment and management. Clin Med (Lond) 2020:clinmed. [PMID: 32165439 DOI: 10.7861/clinmed.cg.20.2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
194 Gubitosi-Klug RA, Sun W, Cleary PA, Braffett BH, Aiello LP, Das A, Tamborlane W, Klein R; Writing Team for the DCCT/EDIC Research Group. Effects of Prior Intensive Insulin Therapy and Risk Factors on Patient-Reported Visual Function Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. JAMA Ophthalmol 2016;134:137-45. [PMID: 26584339 DOI: 10.1001/jamaophthalmol.2015.4606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
195 Orchard TJ, Lyons TJ, Cleary PA, Braffett BH, Maynard J, Cowie C, Gubitosi-Klug RA, Way J, Anderson K, Barnie A, Villavicencio S; DCCT/EDIC Research Group. The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. Diabetes Care 2013;36:3146-53. [PMID: 23813757 DOI: 10.2337/dc12-2661] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
196 Lee CL, Chen CH, Wu MJ, Tsai SF. The variability of glycated hemoglobin is associated with renal function decline in patients with type 2 diabetes. Ther Adv Chronic Dis 2020;11:2040622319898370. [PMID: 32166009 DOI: 10.1177/2040622319898370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
197 Jung HH. Evaluation of Serum Glucose and Kidney Disease Progression Among Patients With Diabetes. JAMA Netw Open 2021;4:e2127387. [PMID: 34586368 DOI: 10.1001/jamanetworkopen.2021.27387] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Limkunakul C, de Boer IH, Kestenbaum BR, Himmelfarb J, Ikizler TA, Robinson-Cohen C. The association of glycated hemoglobin with mortality and ESKD among persons with diabetes and chronic kidney disease. J Diabetes Complications 2019;33:296-301. [PMID: 30795915 DOI: 10.1016/j.jdiacomp.2018.12.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
199 Chen D, Wang M, Shang X, Liu X, Liu X, Ge T, Ren Q, Ren X, Song X, Xu H, Sun M, Zhou H, Chang B. Development and validation of an incidence risk prediction model for early foot ulcer in diabetes based on a high evidence systematic review and meta-analysis. Diabetes Res Clin Pract 2021;180:109040. [PMID: 34500005 DOI: 10.1016/j.diabres.2021.109040] [Reference Citation Analysis]
200 Troya MI, Bonet J, Salinas I, Torres F, Bonal J, Sanmartí A, Romero R. Early intensive treatment improves outcomes in patients with glomerular hyperfiltration and type 2 diabetes. Med Clin (Barc) 2016;146:55-60. [PMID: 26343155 DOI: 10.1016/j.medcli.2015.05.016] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
201 Chatzikyrkou C, Menne J. Diabetes: Legacy effects of RAS blockade in diabetes mellitus. Nat Rev Nephrol 2013;9:566-8. [PMID: 24018412 DOI: 10.1038/nrneph.2013.173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
202 Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, Doria A, Warram JH. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014;37:226-234. [PMID: 23939543 DOI: 10.2337/dc13-0985] [Cited by in Crossref: 172] [Cited by in F6Publishing: 143] [Article Influence: 19.1] [Reference Citation Analysis]
203 Eringa EC, Serne EH, Meijer RI, Schalkwijk CG, Houben AJ, Stehouwer CD, Smulders YM, van Hinsbergh VW. Endothelial dysfunction in (pre)diabetes: characteristics, causative mechanisms and pathogenic role in type 2 diabetes. Rev Endocr Metab Disord 2013;14:39-48. [PMID: 23417760 DOI: 10.1007/s11154-013-9239-7] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 8.8] [Reference Citation Analysis]
204 Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care 2012;35:1265-71. [PMID: 22432116 DOI: 10.2337/dc11-2312] [Cited by in Crossref: 116] [Cited by in F6Publishing: 94] [Article Influence: 11.6] [Reference Citation Analysis]
205 Iuamoto LR, Franco AS, Suguita FY, Essu FF, Oliveira LT, Kato JM, Torsani MB, Meyer A, Andraus W, Chaib E, D'Albuquerque LAC. Human islet xenotransplantation in rodents: A literature review of experimental model trends. Clinics (Sao Paulo) 2017;72:238-43. [PMID: 28492724 DOI: 10.6061/clinics/2017(04)08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
206 Kim SS, Kim JH, Kim IJ. Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes. Endocrinol Metab (Seoul). 2016;31:245-253. [PMID: 27246284 DOI: 10.3803/enm.2016.31.2.245] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
207 Kähler P, Grevstad B, Almdal T, Gluud C, Wetterslev J, Lund SS, Vaag A, Hemmingsen B. Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ Open 2014;4:e004806. [PMID: 25138801 DOI: 10.1136/bmjopen-2014-004806] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
208 Nathan DM. Diabetes: long-acting insulin analogues--are benefits worth the cost? Nat Rev Endocrinol 2012;8:699-700. [PMID: 23147577 DOI: 10.1038/nrendo.2012.208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
209 Bhatt K, Kato M, Natarajan R. Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases. Am J Physiol Renal Physiol 2016;310:F109-18. [PMID: 26538441 DOI: 10.1152/ajprenal.00387.2015] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]